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See Article, pages 1202–1209The bioactive form of vitamin D3, 1,25-dihydroxyvi-
tamin D3 [1,25(OH)2D3], is a secosteroid hormone with
a central function in calcium and bone metabolism, able
to regulate cell proliferation and diﬀerentiation, and
endowed with exquisite immunoregulatory properties
[1]. Vitamin D3 can be obtained through the diet, but
it is mainly biosynthesized from 7-dehydrocholesterol
in skin exposed to ultraviolet light. Vitamin D3 is then
transported to the liver where it is hydroxylated to pro-
duce 25(OH)D, a reliable indicator of vitamin D status,
and is further hydroxylated in the kidney to form the
active hormone, 1,25(OH)2D3 [2]. The biological eﬀects
of 1,25(OH)2D3 are mediated by the vitamin D receptor
(VDR), a nuclear hormone receptor expressed in most
cell types, functioning as a ligand-activated transcription
factor that binds to vitamin D-responsive elements in
the promoter region of target genes, and ultimately
inﬂuences their rate of RNA polymerase II-mediated
transcription [3].
The vitamin D endocrine system is involved in a vari-
ety of biological processes that modulate immune
responses [4], and has an important role in the control
of autoimmune diseases [1]. Vitamin D status is a crucial
environmental factor that aﬀects the prevalence of auto-
immune diseases, as shown by the higher incidence of
several autoimmune diseases in northern latitudes where
lower amounts of vitamin D3 are synthesized from sun-
light exposure [2,5]. Epidemiological analysis reveals0168-8278/$36.00  2009 European Association for the Study of the Liver.
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vitamin D system reduces the risk of several autoim-
mune diseases, including multiple sclerosis, type 1 diabe-
tes, inﬂammatory bowel disease, rheumatoid arthritis,
and systemic lupus erithematosus [2,6]. 1,25(OH)2D3 is
produced by macrophages, dendritic cells (DCs), T
and B cells, and contributes physiologically, via the
VDR expressed in these cell types, to the autocrine
and paracrine regulation of both innate and adaptive
immune responses [4]. In addition to exerting direct
modulatory eﬀects on T and B cell function, VDR ago-
nists inﬂuence the phenotype and function of DCs, pro-
moting tolerogenic properties that favor the induction of
regulatory, rather than eﬀector, T cells [7]. These intrigu-
ing actions of VDR agonists have been demonstrated in
several experimental models of autoimmune diseases
and appear to represent important components of
immune system homeostasis. In addition to psoriasis,
a Th1 and Th17 cell-mediated autoimmune disease of
the skin, VDR agonists could be exploited to treat a
variety of autoimmune diseases and other immune-med-
iated pathologies that are characterized by chronic
inﬂammatory responses [1].
Primary biliary cirrhosis (PBC) is an autoimmune
liver disease characterized by a progressive portal lym-
phocytic inﬂammatory response with destruction of
intrahepatic bile duct epithelial cells leading to cholesta-
sis, liver ﬁbrosis and eventually cirrhosis [8]. The sero-
logical hallmark of the disease is the presence of
circulating anti-mitochondrial antibodies, reﬂecting the
induction of autoreactive T and B cells to the inciting
antigens, mainly E2 subunits of mitochondrial pyruvate
dehydrogenase [9]. Although the etiology of PBC is still
unclear, both genetic and environmental componentsPublished by Elsevier B.V. All rights reserved.
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sion of the disease [10]. Familiarity among PBC patients
is frequently observed, and the prevalence of PBC
clustering in a representative family with aﬀected
patients is much higher than in the general population
[11]. In addition, the concordance rate for PBC is
remarkably higher in monozygotic compared to dizy-
gotic twins, scoring as the highest among autoimmune
diseases [12]. MHC class II polymorphisms were found
to be associated with both increased risk and protection
from PBC in recent large-size studies [13,14]. Con-
versely, analysis of non-MHC gene polymorphisms has
provided inconsistent results, possibly due to small sam-
ple size and ethnic diﬀerences in the frequency of minor
alleles. As a notable exception, analysis of VDR poly-
morphisms has consistently demonstrated an associa-
tion with susceptibility to PBC in diﬀerent populations
[15–18].
DNA sequence variations occurring frequently in
the population are deﬁned as ‘‘polymorphisms” and
can have subtle but real biological eﬀects. Several
polymorphisms have been identiﬁed in the VDR gene,
but their inﬂuence on VDR protein function and sig-
nalling is largely unknown. The genomic organization
of the human VDR locus at chromosome 12q13.1
shows that the VDR gene itself is quite large (over
100 kb) with 11 exons, and has an extensive promoter
region capable of generating multiple tissue-speciﬁc
transcripts [19]. VDR polymorphisms have been ana-
lyzed so far mostly in Caucasians, usually by studying
three adjacent restriction fragment length polymor-
phisms (RFLP) for BsmI, ApaI, and TaqI, respec-
tively, at the 30 end of the VDR gene [19]. Because
these polymorphisms are probably non-functional,
linkage disequilibrium with one or more truly func-
tional polymorphisms elsewhere in the VDR gene, or
in nearby gene/s, is assumed to explain the associa-
tions observed [20].
VDR gene polymorphisms have been found to be
associated with osteoporosis, a common complication
observed in about 25% of PBC patients although not
speciﬁc to the disease [21], in which VDR genotypes
have been reported to predict lower bone mineral den-
sity [22]. However, VDR genotypes may play only a
minor role in the development of osteoporosis in PBC,
where duration and severity of cholestasis are associated
with degree of bone loss and may exceed the potential
eﬀect of gene polymorphisms [23]. Conﬂicting results
have also been reported for the association of VDR gene
polymorphisms with PBC. Studies performed in the
Hungarian population have supported a positive associ-
ation between susceptibility to PBC and BsmI polymor-
phism at the VDR locus [15,17]. Conversely, the
German [16] and Chinese [18] studies have revealed a
protective association of BsmI VDR polymorphism with
PBC. These discrepant results could be due to diﬀerentcauses, including ethnic diversity, relatively small sample
size, linkage disequilibrium, population stratiﬁcation
and environmental confounding factors.
In this issue, Tanaka et al. [24] report the genetic
association of BsmI, ApaI, and TaqI VDR gene poly-
morphisms with PBC in large and well characterized
patient series from Japan and Italy. Results in this paper
indicate that RFLPs for BsmI and ApaI are signiﬁcantly
associated with the susceptibility of PBC, and that the
‘B’ allele is more frequently distributed in PBC patients
[24]. In contrast to previous studies, Tanaka et al. have
analyzed a large number of PBC cases and controls, 334
and 335, respectively, performing three statistical tests
for each genotype. Importantly, this study has investi-
gated VDR allele frequencies in Japanese and Italian
subjects, completely diverse populations but both ethni-
cally homogeneous, thereby preventing population
stratiﬁcation. The signiﬁcant association of BsmI poly-
morphism in both Japanese and Italian populations
indeed suggests a general contribution of VDR gene
polymorphism to PBC susceptibility [24].
The interpretation of polymorphic variations in the
VDR gene is blurred by the fact that until now only a
few polymorphisms in this large gene have been studied
and most are anonymous RFLPs, with an unknown
functional eﬀect. Nevertheless, results from the current
study demonstrate the possibility that VDR polymor-
phism represents a genetic marker for the risk of PBC.
In particular, the odds ratio (OR) of genotype ‘BB’ at
the BsmI polymorphism in Japanese subjects was 13.7,
supporting the rationale that genotype ‘BB’ might be
used as a diagnostic tool and/or a predictive marker
for PBC [24].
In the absence of a clear link between VDR polymor-
phisms and function of the vitamin D endocrine system,
it is possible only to speculate about the underlying
mechanisms. Vitamin D deﬁciency does not appear to
be widespread among PBC patients [25], who experience
a lower frequency of 25(OH)D deﬁciency compared to
other autoimmune diseases [2]. 25-hydroxylation of vita-
min D3, which takes place in the liver, is normal in PBC
patients [26]. Cholestatic liver injury is counteracted by a
variety of adaptive hepatoprotective mechanisms,
including modulation of bile acid transport, synthesis
and detoxiﬁcation, which are mediated by a complex
network of nuclear receptors involving the farnesoid X
receptor, pregnane X receptor, constitutive androstane
receptor, and VDR [27]. VDR also functions as a recep-
tor for the secondary bile acid lithocholic acid [28],
which is hepatotoxic, providing a possible association
between PBC and VDR polymorphisms. Mice treated
with 1,25(OH)2D3 after bile duct ligation (BDL) did
not show decreased bile acid levels in plasma and liver,
but the treatment suppressed mRNA expression of pro-
inﬂammatory cytokines in the liver and strongly
decreased plasma levels of proinﬂammatory cytokines
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tory rather than the cholestatic aspect of the disease. If
the VDR polymorphisms described by Tanaka et al.
reﬂect a deranged capacity of the vitamin D system to
promote tolerogenic DCs, enhance regulatory T cells
and/or inhibit pathogenic Th1 and Th17 cells in PBC
patients, these would represent plausible explanations
for the association of the observed VDR polymorphisms
with PBC.
Future research should document additional poly-
morphisms across the VDR gene to verify these hypoth-
eses, trying to understand the functional consequences
of the receptor variations. Until then, the role of VDR
polymorphisms in PBC, as in any other autoimmune
disease, will remain a topic for debate. Unfortunately,
the complex organization of the VDR gene will make
the identiﬁcation of these functional polymorphisms a
somewhat daunting task.
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